Navigation Links
Longer Time Frame for Clot-Busting Drug May Help Beat Stroke

By Amanda Gardner
HealthDay Reporter

MONDAY, July 26 (HealthDay News) -- Extending the time window to treat stroke patients with the clot-dissolving drug tPA from 3 hours to up to 4.5 hours after the onset of stroke doesn't result in any significant delays in treatment and appears to be a safe option for saving lives, new research suggests.

Still, there was a slight increased risk of death and bleeding over a three-month period in patients who received the later treatment -- a finding that reinforces the idea that the treatment should be given as soon as possible after a stroke to ensure better outcomes, said Swedish researchers reporting in the July 26 online edition of The Lancet Neurology.

"We're still targeting to treat as early as you can because that gets the best results," said Dr. Roger Bonomo, director of stroke care at Lenox Hill Hospital in New York City. "But this gets people included in the treatment group who otherwise would have been excluded just because it was 3 hours and 1 minute or 3 hours and 10 minutes after the stroke," he explained.

"The study is saying that the safety is sufficient to warrant continuing to treat patients [with tPA up to 4.5 hours after a stroke] even though these people have more symptomatic hemorrhages," he added.

Tissue plasminogen activator (tPA), also known as the drug alteplase, is an approved treatment for the most common kind of stroke -- ischemic stroke -- in which a blood vessel that supplies blood to the brain is blocked by a blood clot. The three-hour post-stroke time limit was set because of fears that use of the clot-dissolving drug beyond that period might cause dangerous bleeding or other complications.

After the publication of two landmark studies, the American Heart Association, the American Stroke Association and the European Stroke Association revised their guidelines in October 2008 to recommend that tPA be used up to 4.5 hours after the onset of an ischemic stroke.

Since that time, the number of patients being treated this way has surged.

But despite the initial evidence, experts have been worried that using the longer time window in actual practice might result in unnecessary delays in treatment, an increase in the number of intracerebral hemorrhages and still more deaths.

"There were lots of questions and interest in following up on the change in practice," Bonomo said.

The study authors, from the Karolinska Institute in Stockholm, revisited data on 23,942 patients who had participated in a clinical trial investigating the longer time window for using tPA.

By the end of 2009, three times more patients were being treated in the later time period (3 hours to 4.5 hours) than before the change but the average time from admission to treatment stayed the same, at 65 minutes.

Patients treated in the outer time limit were 44 percent more likely to suffer an intracerebral hemorrhage and 26 percent more likely to die within three months. Still, the authors wrote, these increases "are minor and are outweighed by the benefit of the treatment."

According to an accompanying "reflection and reaction" piece, this elevated risk translated into one additional hemorrhage for every 200 patients treated and one extra death for every 333 patients treated.

Alteplase is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency only for use within the three-hour limit. The accompanying editorial called for regulatory approval to ensure all patients access to the treatment.

The trial was funded partially by Boehringer Ingelheim, which makes alteplase.

More information

The American Stroke Association has more on ischemic stroke.

SOURCES: Roger Bonomo, M.D., director of stroke care, Lenox Hill Hospital, New York City; July 26, 2010, The Lancet Neurology, online

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Biological clock could be a key to better health, longer life
2. Big Smiles, Longer Lives?
3. Perhaps a longer lifespan, certainly a longer health span
4. Black Women Wait Longer for Breast Cancer Diagnosis, Treatment
5. Canadians Leading Longer, Healthier Lives Than Americans
6. Mayo-led research team develop agents that keep insulin working longer
7. Well-tolerated radiotherapy provides longer life to patients with recurrent brain cancer
8. New Hope for the Sleepless: RealSleep Uses Sound To Help Troubled Sleepers Go To Sleep Faster and Stay Asleep Longer
9. Longer Drug Regimen Still Best Against Breast Cancer
10. Intervention program helps breast cancer patients live longer after recurrence
11. iStayYoung Launches – Live Longer, and Better. Free for Seniors 65+
Post Your Comments:
Related Image:
Longer Time Frame for Clot-Busting Drug May Help Beat Stroke
(Date:12/1/2015)... ... 01, 2015 , ... Tympani Inc., announced today that it ... Cisco. This designation recognizes Tympani as having fulfilled the training requirements and program ... the high-end enterprise contact center marketplace. , Ed Kapelinski, President of Tympani stated, ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National Association of ... into its VIP Woman of the Year Circle. She is recognized with this ... exclusively for professional women, boasting 850,000 members and over 200 operating Local Chapters. ...
(Date:11/30/2015)... ... November 30, 2015 , ... Being a caregiver ... the VA Maryland Health Care System, the Caregiver Support Program promotes the health ... a difficult job. Seventy-four percent report that their role as a caregiver has ...
(Date:11/30/2015)... TX (PRWEB) , ... November 30, 2015 , ... ... plastic surgery and dermatology, is proud to announce that its ThermiRFR temperature controlled ... , ThermiRF is an innovative multi-application radiofrequency platform which uses temperature as a ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... and fun atmosphere for Halloween festivities, the Word of Life Christian Church of ... board game, and featuring a giant 1.25 ton pile of candy dubbed “Candy ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 /PRNewswire/ ... its wholly-owned UK subsidiary Proximagen Ltd., today announced a ... oral small molecule inhibitor of Vascular Adhesion Protein 1 ... the treatment of inflammatory disease. The VAP-1 inhibitor is ... --> --> Under the terms of ...
(Date:11/30/2015)... TOKYO , 1 décembre 2015 ... plus grande exposition et conférence d,Asie ... médicaux et sur l,industrie manufacturière, se ... du 20 au 22 avril ... - Photo - ...
(Date:11/30/2015)... 2015 --> ... - Pipeline Review, H2 2015" market research ... pipeline of Endometriosis and helps enhance decision ... to gain competitive advantage. It strengthens R&D ... to produce first-in-class and best-in-class products. ...
Breaking Medicine Technology: